MethylGene Presents Preclinical Data for MGD290, a Hos2 Fungal Inhibitor, at Joint ICAAC/IDSA Annual Meeting

MONTREAL, QUEBEC--(Marketwire - October 27, 2008) - MethylGene Inc. (TSX: MYG) today disclosed preclinical data for MGCD290, a fungal Hos2 inhibitor to be used in combination with azoles for the treatment of fungal infections. MethylGene is currently evaluating MGCD290 in a Phase I clinical trial. The data were presented in two poster sessions at the joint 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / Infectious Disease Society of America (IDSA) 46th Annual Meeting in Washington, DC.
MORE ON THIS TOPIC